Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- OTC Industry Group Keen on Expanding Self-Medication Tax Break: Chief
January 18, 2017
- JPMA Eager for Its Active Involvement in Drug Pricing Debates: Chief
January 18, 2017
- JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs
January 18, 2017
- JGA Corrects Generic Share Data for Past 3 Years; July-Sept. Share at 65.1%
January 16, 2017
- With Annual Revisions, Drug Wholesalers Will Be Negotiating Delivery Prices All Year: JPWA Chief
January 12, 2017
- Tokyo Pharma Chief Naito Prods Govt to Secure Predictability of Pricing System
January 10, 2017
- Building Personal Relationships Will Be Crucial: FPMAJ Director General
January 6, 2017
- Annual Price Revisions Must Not Adversely Affect Distribution Environment: JPWA
December 26, 2016
- Novo’s Ole Moelskov Bech to Helm EFPIA Japan from January
December 26, 2016
- FPMAJ Accepts PMDA’s Fee Raise Plan, but Wants Tradeoff
December 16, 2016
- JMA Wants Adjustment Rate as High as 5%: Yokokura
December 15, 2016
- Daratumumab Affects Transfusion Tests, Scientific Societies Warn
December 13, 2016
- Ongoing Discussions without Chuikyo Deplorable: JPWA Head
December 12, 2016
- Annual Price Revisions Will Demotivate Pharmas, Foreign HQs Harboring Serious Concerns: PhRMA Japan Chief
December 9, 2016
- Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
December 6, 2016
- JPWA Shows Firm Opposition to Annual Revisions
December 5, 2016
- Annual Price Revisions of All Drugs Unacceptable: JMA Chief
December 1, 2016
- Japan, US, Europe Trade Groups Vehemently Oppose Annual Price Revisions
December 1, 2016
- JGA Rebuts Govt Panel Members’ Pricing Reform Proposals in Emergency Statement
November 30, 2016
- Drug Pricing Rules Should Be Fundamentally Reviewed: JMA Chief
November 28, 2016
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…